New therapeutic solutions R&D is a fundamental and crucial activity for Freia Farmaceutici, in order to rise to new therapeutic solutions that respond to unmet medical needs.
Pipeline
Freia faces this commitment by combining its skills and experiences with leading academics and research centers. These partnerships are a vehicle for ever new investment opportunities and represent, in addition to a deepening and expansion of Freia’s scientific network, an enhancement of our knowledge.
Thanks to this commitment, multiple therapeutic solutions are in an advanced stage of development and continue to generate a high interest from the world of research, as evidenced by the high number of collaborations, research agreements and Material Transfer Agreements currently in place with universities, institutions Research and Public and Private Health Structures.
Every day, thanks to new investment, collaboration and partnership opportunities, Freia Farmaceutici is able to find new health requests, opening new research horizons and clinical experimentation.
Cardiometabolic
Currently, our research efforts are focused on new strategies for treating obesity, non-alcoholic fatty liver disease (NASH) and chronic kidney disease both in adults and children. Together, these therapies are aimed at reducing the risk of cardiovascular mortality and morbidity.
Dermatology
In dermatological area, research and development is currently focused on development of new therapeutic solutions for allergies, to find a better treatment of the various stages of atopic dermatitis and to treat ulcers and lip infections; in oncology, to develop innovative approaches to treat of radio and chemo-induced mucositis.
A biocide as hand cream is under autorisation process.
Gynaecology
Freia is committed to helping women to live better, healthier and longer lives.
Female physiology changes throughout a woman’s life, from puberty to menopause and in order to maintain an equilibrium and well-being state, it is important not to underestimate each of these needs.
Freia dedicates its attention to the development of innovative and effective solutions to help women during the most important phases of their lives: fertility, pregnancy, postpartum, osteoporosis, genital inflammation.
Gastroenterology
Freia Farmaceutici is making available new therapeutic solutions for some important and disabling gastroenterological diseases, with the aim of providing an effective, safe and sustainable alternative to patients and their families.
Particularly, Freia current researches are focused on:
Ulcerative colitis, Crohn’s disease and in general from chronic inflammatory bowel diseases (IBD) are spreading more and more, also due to changes related to incorrect lifestyles.
Problems for patients suffering from these pathologies are due to a chronic disability which often makes difficult and painful every daily action: patients themselves are afraid to talk about them, due to the unpleasantness of the symptoms.
Cachexia is a pathological state characterized by loss of appetite, extreme thinness, reduction of adipose and muscle masses, thinning of the skin, weakening, slowing of psychic abilities. Main causes can be: malnutrition, also related to old age, chronic debilitating diseases, severe pathologies of the endocrine system, infectious diseases (such as HIV), senile and non-senile dementia, anorexia nervosa, advanced malignant tumors.
A particular cause of cachexia is due to mechanical or functional problems with swallowing. Alongside nutritional supplementation, it is therefore necessary to develop particular formulations products that are hyper-nutritional but easily ingested and at the same time reduce the risk of ab-ingestis.
Celiac disease is an autoimmune disease causesing damage to small intestine. In such pathology, immune system reacts against the body’s own tissues with a consequent chronic inflammation and progressive destruction of intestinal villous. In many cases, this damage is reversible if you start following a strictly gluten-free diet.